ライフサイエンスコーパス: bacteremia

1 n up to 10 days or 14 days for patients with bacteremia).

2 methicillin-resistant Staphylococcus aureus bacteremia.

3 hospital-onset (HO) gram-negative rod (GNR) bacteremia.

4 antimicrobial treatment in patients who have bacteremia.

5 f enteric fever and non-typhoidal Salmonella bacteremia.

6 targets for the prevention of S. epidermidis bacteremia.

7 response to outcome of Staphylococcus aureus bacteremia.

8 ed 647 consecutive patients with E. faecalis bacteremia.

9 illin-resistant Staphylococcus aureus (MRSA) bacteremia.

10 es, which were significantly associated with bacteremia.

11 ersistent bacteremia (>/= 4 d) and resolving bacteremia.

12 added little value in the management of GNB bacteremia.

13 vancomycin may shorten the duration of MRSA bacteremia.

14 to the GP surgery, 2 of whom died with MRSA bacteremia.

15 E) among patients with Enterococcus faecalis bacteremia.

16 10 hours but without any impact on recurrent bacteremia.

17 for extensively drug-resistant A. baumannii bacteremia.

18 come was time to death from the first day of bacteremia.

19 wed pneumonia, including one with concurrent bacteremia.

20 ed, as determined by measuring mortality and bacteremia.

21 E) mostly occurs after spontaneous low-grade bacteremia.

22 stimate ICU mortality caused by enterococcal bacteremia.

23 failure-free days at Day 14, and duration of bacteremia.

24 ceptible to Escherichia coli peritonitis and bacteremia.

25 s are susceptible to E. coli peritonitis and bacteremia.

26 leukemia who developed invasive A. butzleri bacteremia.

27 ease the risk of postoperative infection and bacteremia.

28 ise and persist during Staphylococcus aureus bacteremia.

29 oxacillin for MSSA infections complicated by bacteremia.

30 while CDON could have a role in complicated bacteremia.

31 UBC and identify risk factors for persistent bacteremia.

32 in 105 patients, of whom 99 had a high-risk bacteremia.

33 es in peripheral white blood cells following bacteremia.

34 produces the toxins that contribute to acute bacteremia.

35 typhi A in stool typically preceded onset of bacteremia.

36 -producing (CP)-CRE compared with non-CP-CRE bacteremia.

37 of hospitalizations due to catheter-related bacteremia.

38 aumannii isolated from a mammalian host with bacteremia.

39 ulopoietic precursor proliferation following bacteremia.

40 lineage-negative marrow cells in response to bacteremia.

41 patients with MSSA infections complicated by bacteremia.

42 re-free days (6 d; P = 0.27) and duration of bacteremia (0 d; P = 0.24).

43 (3.7 to 2.5/1000 patient-days; P=.001), KPC bacteremia (0.9 to 0.4/1000 patient-days; P=.008), all-c

44 6), late post-surgical infection (2.20), and bacteremia (1.69).

45 Sepsis or bacteremia (100 [34.7%]) and recent use of cocaine or ot

46 to 0.4/1000 patient-days; P=.008), all-cause bacteremia (11.2 to 7.6/1000 patient-days; P=.006) and b

47 Of the initial 141 DFU-ISIs, 64% were bacteremia, 13% deep abscesses, 10% pneumonia, 7% endoca

48 if more than 3), 5 points; unknown Origin of bacteremia, 4 points; prior heart Valve disease, 2 point

49 Of 318 episodes of bacteremia, 49 were caused by P. aeruginosa.

50 ter antibiotic treatment (median duration of bacteremia, 53 hours [interquartile range, 24-85 hours])

51 AE reports for viridans group streptococcal bacteremia, a targeted toxicity on AAML0531, had a sensi

52 Primary outcome was persistent bacteremia after 4 days of effective therapy.

53 ped fever, classic eschars, lymphadenopathy, bacteremia, altered liver function, increased WBC counts

54 with bacterial infections-including 32 with bacteremia and 15 with urinary tract infections-and 190

55 Patients with MSSA bacteremia and a reported PCN allergy should have the al

56 ned for their fitness during mouse models of bacteremia and acute pneumonia.

57 In addition, bacteremia and anemia also peaked in these animals at 5

58 al fluid, urine, or stool samples, including bacteremia and bacterial meningitis classified as IBIs.

59 re units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outc

60 hat hepcidin deficiency results in increased bacteremia and decreased survival of infected mice, whic

61 investigate blood volumes required to detect bacteremia and fungemia with low concentrations of an or

62 ajor cause of severe infections that lead to bacteremia and high patient mortality.

63 occus gallolyticus is an increasing cause of bacteremia and infective endocarditis in the elderly.

64 ns caused a variety of infections, including bacteremia and invasive and disseminated diseases, parti

65 um of immunocompromised patients can lead to bacteremia and life-threatening sepsis.

66 Lactobacilli can lead to bacteremia and liver abscesses in some susceptible perso

67 Cigarette smoke increased the risk of bacteremia and meningitis without prior lung infection.

68 also a potential source for life-threatening bacteremia and metastatic abscesses.

69 umoniae NP density to increase, resulting in bacteremia and mortality.

70 ld's leading cause of pneumonia, meningitis, bacteremia and otitis media.

71 nella antimicrobial resistance may result in bacteremia and poor outcomes.

72 ous clinical conditions, including sepsis or bacteremia and recent use of cocaine or other illicit dr

73 (lincRNA) gene (AC011288.2) and pneumococcal bacteremia and replicated the results in the same popula

74 nd cumulative effect of multiple episodes of bacteremia and sepsis across multiple hospitalizations o

75 We report the first known case of bacteremia and sepsis due to Kerstersia gyiorum, in a pa

76 Bacteremia and sepsis occurred during 4923 (3.1%) and 55

77 , to estimate the marginal causal effects of bacteremia and sepsis on developing the first observed i

78 Prior instances of bacteremia and sepsis substantially increase the 5-year

79 s fragilis is the leading cause of anaerobic bacteremia and sepsis.

80 ly, Rsp was essential for the development of bacteremia and skin infection, representing major types

81 N or SLO are significantly attenuated in the bacteremia and soft tissue infection models, and the mut

82 e cPLA2alpha-deficient mice also suffered no bacteremia and survived a pulmonary challenge that was l

83 s to biofilm-associated infections and acute bacteremia and that this is likely due to agr-independen

84 mice, there was a direct correlation between bacteremia and the number of bacteria in the brain, whic

85 are involved in the CRP-mediated decrease in bacteremia and the resulting protection of mice against

86 of 154 isolates from hospital patients with bacteremia and those with blood culture contaminants and

87 yocardium occurred soon after development of bacteremia and was continuous thereafter.

88 Patients with bacteremia and were present in the ICU at the time cultu

89 sive bacterial infections (IBIs), defined as bacteremia and/or bacterial meningitis, using complete b

90 accine efficacy using endpoints that include bacteremia and/or symptomatology.

91 Salmonella species account for 24%-59.8% of bacteremias and are the commonest cause of childhood bac

92 3 respiratory patients that resulted in two bacteremias and one lower respiratory tract infection.

93 and pyelonephritis, a fitness factor during bacteremia, and a surface-accessible target of the exper

94 bacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identi

95 ssion is an associated factor for pneumonia, bacteremia, and death due to A. baumannii.

96 , including urinary tract infections (UTIs), bacteremia, and infective endocarditis.

97 fections (UTIs), is a leading cause of adult bacteremia, and is the second most common cause of neona

98 ibited higher urine pH values, urolithiasis, bacteremia, and more pronounced tissue damage and inflam

99 was a risk factor associated with pneumonia, bacteremia, and mortality.

100 e intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT.

101 location, serum interleukin-6 (IL-6) levels, bacteremia, and sepsis mortality.

102 nce in mouse models of necrotizing myositis, bacteremia, and skin and soft tissue infection.

103 th regard to the prevention of S. pneumoniae bacteremia, and there was no difference in mortality.

104 , disease severity, comorbidities, source of bacteremia, and type of organism.

105 ght information regarding presumed source of bacteremia, antibiotic status at the time of FUBC, antib

106 ed Kingdom shows that the proportion of MRSA bacteremias apportioned to hospitals is decreasing, sugg

107 rica; however, few data on the burden of NTS bacteremia are available.

108 ogenous implant-related infections following bacteremia are particularly problematic because they can

109 any antimicrobial agents, with pneumonia and bacteremia as the most common manifestations of disease.

110 were strongly protected against pyoderma and bacteremia, as evidenced by a 100-1000-fold reduction in

111 of Streptococcus agalactiae and detection of bacteremia at <1 CFU/ml were unreliable.

112 id was notable for high rates of subclinical bacteremia (at this dose, 11/20 [55%]).

113 Bacteremia (bacterial bloodstream infection) is a major

114 miology, antibiotic therapy, and outcomes of bacteremia because of extensively drug-resistant (XDR) P

115 Bacteremia because of XDR P. aeruginosa should be carefu

116 e during the peaks of lipopolysaccharide and bacteremia but not of TAT and PAP.

117 eath, and disrupt cardiac function following bacteremia, but it is unknown whether the same occurs in

118 o accelerate the clearance of S. epidermidis bacteremia, but TLR2(-/-)mice could still resolve a bloo

119 n of extended-spectrum beta-lactamase (ESBL) bacteremia can improve clinical outcomes while minimizin

120 Both the blood-culture-proven bacteremia case subjects and healthy infants as controls

121 ce of methicillin-resistant S. aureus (MRSA) bacteremia cases are classified as persistent and are as

122 Staphylococcus aureus bacteremia cases are complicated by bacterial persistenc

123 onella (NTS) accounted for 10.8% and 5.8% of bacteremia cases in children and adults, respectively, w

124 ng from two independent persistent S. aureus bacteremia cases with the initial infection isolates and

125 by intravenous injection of Escherichia coli Bacteremia caused a remarkable increase in marrow lin(-)

126 For bacteremia caused by 3GC-R EB, PPVs of prior colonizatio

127 tality of intensive care unit (ICU)-acquired bacteremia caused by enterococci.

128 ribe severe community-acquired pneumonia and bacteremia caused by Herbaspirillum aquaticum or H. hutt

129 can protect against pyoderma and subsequent bacteremia caused by multiple GAS strains, including str

130 describe a case of an infant with recurrent bacteremia caused by Streptococcus equi subsp. zooepidem

131 mpiric antibiotic treatment in patients with bacteremia caused by third-generation cephalosporin (3GC

132 vaccination of mice decreased survival in a bacteremia challenge model.

133 Monomicrobial E. faecalis bacteremia, community acquisition, prosthetic heart valv

134 ycin, the antibiotic of choice to treat MRSA bacteremia, could not penetrate the KCs to eradicate int

135 Using a bacteremia-derived meningitis model and mutant mice, as

136 Rsp inactivation in laboratory- and bacteremia-derived mutants attenuates toxin production,

137 Since the current gold standard for bacteremia diagnosis is based on conventional methods de

138 e-quarters of all culture-confirmed cases of bacteremia directly from blood in significantly less tim

139 ineffectual in preventing skin infection and bacteremia due to CovR/S mutants but that the combinatio

140 We included patients >/=18 years of age with bacteremia due to Escherichia coli or Klebsiella species

141 tive cohort included all patients who had HO bacteremia due to Escherichia coli, Klebsiella species,

142 f immunosuppressive therapy, neutropenia, or bacteremia due to multidrug-resistant organisms.

143 MCs (p = 0.04), reduced eschar frequency and bacteremia duration (p </= 0.01), delayed bacteremia ons

144 total of 11 196 patients experienced HO-GNR bacteremia during the study period.

145 were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and

146 blood samples from 913 patients suspected of bacteremia (enrollment criteria were physician-ordered b

147 Of bacteremia episodes caused by 3GC-R and 3GC-sensitive EB

148 type bacteremia without misclassification of bacteremia episodes due to non-PCV13 serotypes.

149 s of extensively drug-resistant A. baumannii bacteremia evaluated, 55 patients with a median (interqu

150 ith C57BL/6J mice, DBA/2J mice had increased bacteremia, excessive dissemination to the spleen, and e

151 an 82 year old female with liver abscess and bacteremia from lactobacillus after using probiotics con

152 classifier genes distinguished infants with bacteremia from those without bacterial infections in th

153 ithout bacterial infections and infants with bacteremia from those without bacterial infections.

154 ed to BacT/Alert 3D (BTA3D) for detection of bacteremia/fungemia in four bottle types, SA and FA Plus

155 Gram-negative bacteremia (GNB) is a major cause of illness and death a

156 they were more likely to die than resolving bacteremia group (28% vs 5%; p < 0.001).

157 tent bacteremia group than for the resolving bacteremia group (tissue necrosis factor: 26.95 vs 18.38

158 t, levels remained higher for the persistent bacteremia group than for the resolving bacteremia group

159 Compared with resolving bacteremia group, persistent bacteremia patients had hig

160 crobiologic failure, defined as clearance of bacteremia >/=4 days after the index blood culture.

161 t and compared between those with persistent bacteremia (>/= 4 d) and resolving bacteremia.

162 Enterococcal bacteremia has been associated with high case fatality,

163 etic predisposition to Staphylococcus aureus bacteremia has been demonstrated in animals, suggesting

164 associated with urinary tract infections and bacteremia has been intensively investigated, including

165 system demonstrating transmission following bacteremia has been lacking, and thus implications of wi

166 Monomicrobial E. faecalis bacteremia (hazard ratio [HR], 3.60; 95% confidence inte

167 s afforded protection from S. aureus-induced bacteremia in a murine renal abscess model, attenuating

168 Salmonella (iNTS) has emerged as a cause of bacteremia in African children and HIV-infected adults,

169 ella Typhi is the leading cause of childhood bacteremia in central Nigeria.

170 s with nontyphoidal Salmonella (NTS) lead to bacteremia in children and adults and are an important c

171 icin for uncomplicated Enterococcus faecalis bacteremia in children.

172 leading cause of pneumonia, meningitis, and bacteremia in children.

173 The primary outcome was the duration of MRSA bacteremia in days.

174 rospectively reviewed cases of Gram-negative bacteremia in hospitalized patients over a 6-month perio

175 antimicrobial treatment for patients who had bacteremia in ICU.

176 bial treatment provided to patients who have bacteremia in ICUs, to assess pathogen/patient factors r

177 pathogen that primarily causes pneumonia and bacteremia in immunocompromised individuals.

178 occus pneumoniae is the most common cause of bacteremia in Kilifi and was thus the focus of this stud

179 in IA3902 led to the complete abolishment of bacteremia in mice and abortion in pregnant guinea pigs,

180 ounts and a significantly longer duration of bacteremia in mice.

181 vascular pathogens that produce long-lasting bacteremia in reservoir-adapted (natural host or passive

182 but additionally it causes potentially fatal bacteremia in some immunocompromised patients.

183 lineage II pathovar commonly causes systemic bacteremia in sub-Saharan Africa.

184 The frequency and persistence of bacteremia in the absence of clinical symptoms was notab

185 nomial model, the mean time to resolution of bacteremia in the combination group was 65% (95% confide

186 lar bacterial cell numbers (ie, the level of bacteremia), in patients at the time of clinical present

187 ies, there was a sustained decline in HO-GNR bacteremia incidence rates after the implementation of t

188 ulative effect of the intervention on HO-GNR bacteremia incidence rates at the end of the study perio

189 was a significant change of slope in HO-GNR bacteremia incidence rates from before the initiative (+

190 sification tree for predicting ESBL-positive bacteremia included 5 predictors: history of ESBL coloni

191 revalence of shock, major organ dysfunction, bacteremia, inflammatory markers, and lactic acidemia.

192 tantly, it is also demonstrated that E. coli bacteremia initiated from translocation across the intes

193 Enterobacter bacteremia, invasive aspergillosis, and disseminated Can

194 treatment agents in patients with Salmonella bacteremia is a concern for public health and for inform

195 Bacteremia is a life-threatening condition for which ant

196 t of extended-spectrum beta-lactamase (ESBL) bacteremia is controversial.

197 Currently, the management of gram-negative bacteremia is determined by clinical judgment.

198 Gram-negative bacteremia is highly fatal, and hospitalizations due to

199 S. aureus bacteremia is often associated with an adverse outcome.

200 illin-resistant Staphylococcus aureus (MRSA) bacteremia is reaching epidemic proportions causing morb

201 Gram-negative bacilli (GNB) bacteremia is typically transient and usually resolves r

202 of antimicrobial treatment for patients with bacteremia is unknown.

203 n concentration, driven by a higher level of bacteremia, is a key mediator of IL-10 anti-inflammatory

204 The persistent bacteremia isolates (n = 5) formed significantly stronge

205 n isolates and with three resolved S. aureus bacteremia isolates from the same genetic background.

206 practice, and suggests that universal WGS of bacteremia isolates may help detect outbreaks in low-sur

207 Few were infected with genetically identical bacteremia isolates.

208 cally significant differences in duration of bacteremia, length-of-stay, infection-related length-of-

209 A total of 1288 patients with bacteremia met eligibility criteria.

210 f xerC also attenuated virulence in a murine bacteremia model, as assessed on the basis of the bacter

211 In a mouse Escherichia coli bacteremia model, treatment with macrophage mimicking na

212 a useful prognostic marker of P. aeruginosa bacteremia mortality.

213 t isolates were clinically significant, with bacteremia (n = 5), soft tissue infections (n = 3) osteo

214 3080 admissions, 266 events of ICU-acquired bacteremia occurred in 218 (7.1%) patients, of which 76

215 Persistent bacteremia occurred in 24% of patients (47/196); they we

216 ilures, and no S-ICD-related endocarditis or bacteremia occurred.

217 All episodes of bacteremia occurring in SOT recipients were prospectivel

218 aired the virulence and the ability to cause bacteremia of P. aeruginosa.

219 ual immune response to Staphylococcus aureus bacteremia on outcome has not been well studied.

220 nd bacteremia duration (p </= 0.01), delayed bacteremia onset (p < 0.05), reduced circulating bacteri

221 imens were obtained at Staphylococcus aureus bacteremia onset and 72 hours after therapy initiation.

222 Bacteremia or bloodstream infection is a frequent and co

223 cebo group, P = .16), incidence of secondary bacteremia or fungemia (15% for the ganciclovir group vs

224 cal ventilation days, incidence of secondary bacteremia or fungemia, ICU length of stay, mortality, a

225 om patients with concurrent non-B. anthracis bacteremia or nonbacteremic controls.

226 ed by inverse probability weighting (IPW) of bacteremia or sepsis and IPW of censoring, to estimate t

227 ) higher in patients with prior instances of bacteremia or sepsis, respectively, compared to those wi

228 538 (12.0%) patients with prior episodes of bacteremia or sepsis, respectively, vs 3087 (7.2%) and 2

229 63 (7.0%) patients without prior episodes of bacteremia or sepsis.

230 h) in the focal pneumonia model, which lacks bacteremia or sepsis.

231 t S. aureus infection in patients at risk of bacteremia or surgical wound infection but failed to rea

232 ature >/=38 degrees C for >/=12 hours and/or bacteremia) or at day 14 postchallenge.

233 th regard to comorbid conditions, sources of bacteremia, or numbers of intensive care unit (ICU) admi

234 ssion, age of more than 65 years, cirrhosis, bacteremia (p </= 0.001 for each), and urinary sepsis (p

235 endent risk factor for pneumonia (P < .001), bacteremia (P = .005), and death (P = .049).

236 with resolving bacteremia group, persistent bacteremia patients had higher initial median levels of

237 hree-month mortality was higher in high-risk bacteremia patients without (18)F-FDG PET/CT performed t

238 Despite limited symptoms, bacteremia persisted for up to 96 hours after antibiotic

239 removal should be consider for patients with bacteremia, persistent symptoms despite anticoagulation,

240 ial contacts, and pets on the risk of fever, bacteremia, pneumonia, and gastroenteritis.

241 incidence ratios of fever of unknown origin, bacteremia, pneumonia, and gastroenteritis.

242 gery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 or 3, and underlying c

243 Efficient clearance of bacteremia prevents life-threatening disease.

244 er of positive blood cultures, Origin of the bacteremia, previous Valve disease, Auscultation of hear

245 Outcomes examined included bacteremia, pulmonary complications, acute renal failure

246 ulticenter, clinical trial, adults with MRSA bacteremia received vancomycin 1.5 g intravenously twice

247 Etiologic agents of childhood bacteremia remain poorly defined in Nigeria.

248 (IL-10) production in Staphylococcus aureus bacteremia (SaB) animal models, but clinical data are no

249 Importance: Staphylococcus aureus bacteremia (SAB) in children causes significant morbidit

250 Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacte

251 roduction and its association with S. aureus bacteremia (SaB) mortality.

252 antibody in serum of patients with S. aureus bacteremia (SAB), and clinical outcomes in 100 hemodialy

253 tcome in patients with Staphylococcus aureus bacteremia (SAB).

254 rove the management of Staphylococcus aureus bacteremia (SAB).

255 ortant complication of Staphylococcus aureus bacteremia (SAB).

256 I}, 1.02-1.10], per added year) and the Pitt bacteremia score (OR, 1.65 [95% CI, 1.44-1.94], per unit

257 Persistence of bacteremia, shock, respiratory failure and intensive car

258 conducted a genome-wide association study of bacteremia susceptibility in more than 5,000 Kenyan chil

259 ningitis is widely considered to result from bacteremia that leads to blood-brain barrier breakdown a

260 gainst this clonal group in murine models of bacteremia that recapitulate clinical infections.

261 for children with uncomplicated E. faecalis bacteremia, the addition of low-dose gentamicin may decr

262 Among 1,202 ICU patients with bacteremia, the median duration of treatment was 14 days

263 res were monitored at PLGH for Lactobacillus bacteremia through the 10 years' experience, and no Lact

264 blood cultures, we analyzed 500 episodes of bacteremia to determine frequency of FUBC and identify r

265 with extensively drug-resistant A. baumannii bacteremia, treated with colistin-carbapenem and colisti

266 Critically ill patients who have bacteremia typically receive long courses of antimicrobi

267 ough extensively drug-resistant A. baumannii bacteremia under steady state concentrations of combinat

268 djusting for severity of illness on day 1 of bacteremia, underlying medical conditions, and differenc

269 this study, we evaluated the role of CPS in bacteremia using a mouse model and in abortion using a p

270 d and sensitive assay to detect B. anthracis bacteremia using a system that is suitable for point-of-

271 hances GAS virulence, assessed by a model of bacteremia using human plasminogen-expressing mice.

272 ital-based survey of E. coli associated with bacteremia using isolates collected from across England

273 The mean duration of bacteremia was 3.00 days in the standard therapy group a

274 process, as thrombosis peaked at times when bacteremia was absent and bacteria in tissues were reduc

275 Bacteremia was associated with male sex, age >/=65 years

276 Klebsiella bacteremia was demonstrated in 25 to 33% and 10 to 16% o

277 Bacteremia was demonstrated within 24 h in 50 to 88% of

278 For 194 patients (15%), bacteremia was due to a confirmed ESBL producer.

279 Salmonella bacteremia was found in only 16 to 29% and 0% of mice wi

280 significant familial clustering of S aureus bacteremia was found, with the greatest relative rate of

281 Enterococcal bacteremia was independently associated with an increase

282 Bacteremia was induced by intravenous injection of Esche

283 Sensitivity was not compromised: true bacteremia was noted in 65/904 (7.2%) ISDD vs 69/904 (7.

284 A higher rate of S aureus bacteremia was observed among these first-degree relativ

285 Time from transplantation to bacteremia was shorter in XDR P. aeruginosa group compar

286 sulted in slightly accelerated mortality but bacteremia was unaffected.

287 Of 500 episodes of bacteremia, we retrospectively analyzed 383 (77%) that h

288 tient) previously hospitalized with S aureus bacteremia were followed up for a median of 7.8 years (i

289 ypic traits specific to S. aureus persistent bacteremia were identified by comparing temporally dispe

290 2007 and April 2014 with monomicrobial ESBL bacteremia were included.

291 with extensively drug-resistant A. baumannii bacteremia were prospectively followed from 2010 to 2013

292 e 10 years' experience, and no Lactobacillus bacteremias were detected.

293 ic therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a ca

294 Bacteremia with hematogenous dissemination was first det

295 Community-acquired (CA) bacteremia with same species was also analyzed as nonequ

296 ias and are the commonest cause of childhood bacteremia, with a predominance of Salmonella enterica s

297 dardized incidence ratios (SIRs) of S aureus bacteremia, with the incidence rate in the population as

298 ould help treat patients with Staphylococcal bacteremia without a need for novel antibiotics by targe

299 inical outcomes of children with E. faecalis bacteremia without endocarditis receiving ampicillin mon

300 identified 6/7 patients with PCV13 serotype bacteremia without misclassification of bacteremia episo